Hereditary Familial Cutaneous Melanoma Risk Panel (2 genes)

<table>
<thead>
<tr>
<th>CDK4</th>
<th>CDKN2A</th>
</tr>
</thead>
</table>

Indication
This Hereditary Familial Cutaneous Melanoma Risk Panel includes two genes associated with hereditary predisposition to melanoma and other cancers. Most cases of melanoma are isolated and sporadic. However, a small proportion of individuals (approximately 10%) have a family history of the disease typically caused by inherited genetic mutation that increase the risk of developing this type of cancer. Several genes have been associated with hereditary melanoma, including CDKN2A and CDK4. Individuals with inherited pathogenic variant in CDKN2A have 28-67% risk for developing melanoma. Identifying individuals with genetic predisposition to melanoma can allow increased frequency and younger age of initiating screening for cancer, close monitoring of dysplastic nevi for signs of malignant transformation, risk-reducing clinical management options and lifestyle changes, and identification of at-risk family members.

Hereditary cancer syndrome is a genetic predisposition to develop certain types of cancers, often at an early age. Hereditary cancer risk assessment is performed to identify patients and families who may be at risk. Clues that a hereditary cancer syndrome may be present include the following:

- Cancer diagnosed at an unusually young age
- Multiple primary melanomas in the same person
- Skin findings, such as multiple nevi
- Personal or family history of melanoma and other associated cancer types such as pancreatic, breast, ovarian, uterine, prostate, or kidney cancer (mesothelioma)
- A family history of a mutation in a gene that predisposes to melanoma
- The presence of birth defects that are known to be associated with inherited cancer syndromes
- Occurrence of certain types of adult cancer in which the probability of harboring a hereditary cancer syndrome is high (e.g., triple negative breast cancer; ovarian, tubal or peritoneal cancer; male breast cancer)

Testing method
Next Generation Sequencing (NGS) provides coverage of all coding exons and noncoding DNA in exon-flanking regions (on average 50 bp) enriched using hybrid capture Illumina TruSight Cancer Sequencing Panel. Single base pair (point) mutations, small insertions/deletions (1-25 bp), complex insertions and deletions, or larger deletions and duplication (<100 bp) are detected using a combination of clinically validated computational data analysis methods for sequence variant calling, filtering, and annotation. Gross deletions and duplications at each targeted gene and exon are evaluated through comparative depth of coverage analysis of NGS targeted sequencing data using clinically-validated analysis algorithm.
All reportable copy number variants are confirmed by independent methodology using gene-specific Multiplex Ligation-dependent Probe Amplification (MLPA) or genome-wide SNP microarray assay.

**Turnaround time**
5-10 business days

**Sample requirements**
3 ml peripheral blood in EDTA (lavender) top tube
Specimen stability: Ambient - 72 hours; Refrigerated - 1 week

**CPT codes**
81404, G0452

**References**


**Ship Specimens to:**
Henry Ford Center for Precision Diagnostics
Henry Ford Hospital
Clinic Building, K6, Core Lab E-655
2799 W. Grand Blvd.
Detroit, MI 48202